Inventiva (NASDAQ:IVA) Rating Increased to Strong-Buy at Wolfe Research

Wolfe Research upgraded shares of Inventiva (NASDAQ:IVA) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other equities analysts also recently weighed in on the company. HC Wainwright lifted their target price on Inventiva from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Guggenheim increased their target price on shares of Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Piper Sandler began coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.75.

Inventiva Stock Performance

IVA opened at $4.18 on Thursday. Inventiva has a 52 week low of $2.11 and a 52 week high of $7.98. The business has a fifty day simple moving average of $5.40 and a 200-day simple moving average of $4.18.

Institutional Investors Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,715 shares of the company’s stock, valued at approximately $32,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.